# Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence

> **NCT03512249** · PHASE2 · COMPLETED · sponsor: **International AIDS Vaccine Initiative** · enrollment: 831 (actual)

## Conditions studied

- Tuberculosis, Pulmonary

## Interventions

- **BIOLOGICAL:** H56:IC31
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03512249
- **Lead sponsor:** International AIDS Vaccine Initiative
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-31
- **Primary completion:** 2023-03-20
- **Final completion:** 2023-03-20
- **Target enrollment:** 831 (ACTUAL)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03512249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03512249, "Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT03512249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*